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ABSTRACT
Objective: The objective of the present study is to perform the molecular docking studies of some newly designed chroman analogs on estrogen 
receptor (ER) (PDB: 1YIM) by Glide v5.0.
Methods: The docking studies of designed chroman analogs were performed on the active site of ER (PDB: 1YIM) for anti-breast cancer activity using 
Schrodinger Glide v5.0. Absorption, distribution, metabolism, excretion properties of all designed compounds were also calculated by Qik Prop v3. 0.
Results: Among all compounds, compound 38 showed highest docking score (−8.17) in the series. Docking scores were compared with standard 
drugs tamoxifene (−11.08) and anastrazole (−7.86). All compounds were found to be within expectable range for percent human oral absorption, 
octanol/water partition coefficient (QP log Po/w), brain/blood partition coefficient (QP log BB), total solvent accessible surface area, and rule of five 
predicted by Qikprop.
Conclusion: Most of the compounds in the series showed good molecular docking score on the ER (PDB: 1YIM). Compound 38 (−8.16) exhibited 
better docking score than standard drug anastrazole (−7.86). Most of the pharmacokinetic properties conducted by Qikprop were found to be within 
the permissible range.
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INTRODUCTION
Among all cancers, breast cancer is one of the most common diagnosed 
cancers in the world. It creates a major health problem among women 
and consider as the second leading deaths in women [1]. The main 
cause includes age, personal health history, family health history, diet, 
exercise, and obesity. Although various forms of treatment available 
but the treatment is limited due to the resistant to chemotherapy and 
endocrine therapy [2]. Therefore, it is an urgent need to develop new 
effective drug for the treatment of breast cancer.
Estrogen receptor (ER) is found to be overexpressed in more than 60% 
cases of human breast cancers [3]. Designing drug-like molecules that 
can fit to the alpha ligand-binding domain of ER will be a promising 
starting point in developing anti-breast cancer drugs [4]. Recently, 
chroman molecules have received great attention in this field [5-8]. 
Chroman is an important class of oxygen containing heterocyclic 
compounds having many interesting activities, such as insulin release 
process inhibitors [9], human rhinovirus capsid-binding inhibitors [10], 
neuroprotective [11], antiestrogens [12], antioxidant [13], selective 
serotonin reuptake inhibitors [14], anti-HIV [15], antiarrythmic [16], 
and potassium channel activators [17], and well-tolerated in human 
subjects.
Therefore herein, we have designed some new chroman analogs by 
replacing nitrogen from chroman hydrazide with different substituted 
isatin and anhydride molecules and evaluated their binding ability to ER 
by molecular docking. As per the available literature, various chroman 
analogs had been designed and docked on ER, but chroman hydrazides 
containing isatin and anhydride molecules are new compounds and 
have not been docked.
METHODS
Structure selection and preparation for docking studies
The interactions and selectivity of the designed compounds 
were observed for alpha ligand-binding domain of ER. The X-ray 
crystallographic structures of the ER (PDB: 1YIM) were obtained 
from Protein Data Bank (www.rcsb.org) and prepared for molecular 
modeling [4]. Ligands were prepared using Maestro (v8.5) and 
minimized. An extensive set of conformations were generated using 
a liquid simulations-2005 (OPLS 2005) force field in solvent water 
conditions. Ligpreps were generated for three-dimensional co-ordinates 
of the conformers, their stereochemical, ionization, and tautomeric 
variations. The docking procedure was validated by extracting ligand 
CM4 from the binding site and re-docking it to the ER (PDB: 1YIM). Glide 
had successfully reproduced the experimental binding conformations 
of CM4 in ER with an acceptable root-mean-square deviation of 1.87 Å.
Docking studies
All ligands were docked with the obtained ligprep conformers into the 
active site of ER using the extra precision settings of the docking panel 
with default settings.
Absorption, distribution, metabolism, excretion (ADME) studies
In silico, ADME properties of the compounds (1-40) were calculated 
using QikProp (v3.1) module of Schrodinger [18]. It helps in predicting 
both the physically significant descriptors and pharmaceutically 
relevant properties. Different parameters such as predicted aqueous 
solubility (Log S), predicted apparent MDCK cell permeability (PMDCK), 
percent human oral absorption, octanol/water partition coefficient 
(QP log Po/w), brain/blood partition coefficient (QP log BB), and total 
solvent accessible surface area (SASA) were calculated. All compounds 
were neutralized before being used by QikProp. Compounds were also 
evaluated for acceptability of the inhibitors based on the Lipinski’s rule 
of 5, which is necessary for rational drug design.
RESULTS AND DISCUSSION
Design and molecular docking
Various compounds were designed by doing the substitution of 
chroman hydrazides by different isatin and anhydride molecules using 
chemoffice 2004 software and docking studies were performed by 
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Glide v5.0 [19] (Schrodinger-Maestro) for all the designed compounds 
against ER. Table 1 showed the docking scores of designed compounds 
(1-40) along with standard drugs. Docking score of compounds 
ranges between −4.00 and −8.17. All compounds showed less docking 
score than tamoxifene (−11.08). Compound 38 having citraconic 
anhydride possessed better docking score (−8.17) than standard drug, 
anastrazole (−7.86). Compounds 38, 36, 35, 26, 39, 11, 18, 5, and 27 
exhibited good score (−8.17, −7.83, −7.66, −7.64, −7.50, −7.40, −7.34, 
−7.34, and −7.05, respectively). Compounds 14 showed lowest docking 
score (−4.00).
Ligand-receptor interactions for all docked compounds were analyzed 
on the basis of hydrogen bonding because H-bond plays a significant 
role in the structure and function of biological molecules. The carbonyl 
group (-COC<) of anhydrides of compounds 21, 26, 27, 29, 30, and 
carbonyl group (-CONHNH-) of compounds 2, 5, 8, 10, 11, 22, 23, 31, 
32, interacted with CYS530 through their carbonyl oxygen atoms. While 
this carbonyl oxygen atom in highest docking scored compound 38, 
on other hand, involved in hydrogen bonding interaction with LYS531 
(Fig. 1). The hydroxyl oxygen atom formed H-bond with LEU387 in 
compound 3, 18, 26, 27, and with GLU353 in compounds 21, 28, 29.
Table 1: Docking scores of designed chroman analogs (1‑40) and standard drugs
Entry R Rꞌ Docking score Entry R Rꞌ Docking score
1 H −6.50 22 H −6.38
2 H −6.80 23 H −6.92
3 H −6.24 24 H −6.50
4 H −5.59 25 H −5.53
5 H −7.34 26 H −7.64
6 H −5.87 27 H −7.05
7 H −4.83 28 H −4.51
8 CH3 −6.95 29 H −6.32
9 CH3 −5.65 30 CH3 −5.42
(Contd...)
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Entry R Rꞌ Docking score Entry R Rꞌ Docking score
10 CH3 −6.32 31 CH3 −5.67
11 CH3 −7.40 32 CH3 −4.88
12 C6H5 −6.04 33 CH3 −6.00
13 C6H5 −6.79 34 CH3 −5.94
14 C6H5 −4.00 35 C6H5 −7.66
15 C6H5 −5.00 36 C6H5 −7.83
16 C6H5 −6.91 37 C6H5 −5.34
17 C6H5 −6.95 38 C6H5 −8.17
18 H -NH2 −7.34 39 C6H5 −7.50
19 CH3 -NH2 −6.74 40 C6H5 −6.94
20 C6H5 -NH2 −5.25 Tamoxifene −11.08
21 H −6.92 Anastrazole −7.86
Table 1: (Continued)
Asian J Pharm Clin Res, Vol 8, Issue 6, 2015, 88-92
 Rawat and Verma 
91
Compounds containing anhydride groups showed better docking score 
as compare to compounds with isatin. R substitution by benzyl group 
seems to increase its binding profile. It had been observed that the 
top docking scored compounds interacted within the active site of the 
enzyme in a similar way. Interaction diagrams of best docked compound 
38 showed in Fig. 2.
ADME studies
ADME properties of titled compounds (1-40) such as predicted aqueous 
solubility (Log S), predicted apparent MDCK cell permeability (PMDCK), 
percent human oral absorption, octanol/water partition coefficient 
(QP log Po/w), brain/blood partition coefficient (QP log BB), SASA, 
and rule of five were predicted by Qikprop v3.0 (Table 2). The human 
oral absorption percentage of all compounds was in the appropriate 
Table 2: Pharmacokinetic properties (ADME) of titled compounds (1‑40)
Comp Log S PMDCK Percentage oral absorption QP log Po/w QP log BB SASA Rule of five
1 −5.379 99.717 89 3.463 −1.289 640 0
2 −6.470 196.011 100 4.158 −0.884 707 0
3 −5.864 196.145 92 3.904 −1.155 654 0
4 −6.701 258.248 95 4.245 −1.321 698 0
5 −5.983 192.493 81 3.890 −1.215 664 0
6 −5.626 152.632 91 3.668 −1.207 645 0
7 −6.990 439.954 100 4.669 −0.998 720 0
8 −5.970 290.597 100 4.305 −0.887 668 0
9 −6.222 429.852 100 4.563 −0.832 672 0
10 −6.007 347.939 100 4.336 −0.902 662 0
11 −6.789 697.295 91 4.810 −0.774 697 0
12 −6.717 370.173 100 5.643 −1.276 758 1
13 −7.550 442.614 100 6.231 −0.938 801 1
14 −6.751 659.196 87 6.035 −0.754 716 2
15 −6.866 663.180 87 5.822 −1.215 726 2
16 −7.704 1111.1 94 6.560 −0.681 796 2
17 −7.407 366.883 83 5.966 −0.695 742 2
18 −3.138 159.633 81 1.413 −0.941 736 0
19 −3.546 361.199 91 2.108 −0.635 521 0
20 −4.846 351.993 100 3.588 −0.835 619 0
21 −5.786 143.891 92 3.410 −1.194 639 0
22 −7.512 2546.7 88 4.884 −0.360 675 2
23 −7.252 2796.1 88 4.910 −0.517 703 1
24 −6.041 267.400 92 3.650 −1.044 680 0
25 −4.512 79.574 81 2.342 −1.279 631 0
26 −5.307 17.520 74 3.044 −1.906 677 0
27 −4.441 218.664 90 2.526 −0.892 597 0
28 −5.147 137.684 88 2.769 −1.173 638 0
29 −5.668 −5.812 95 3.468 −0.744 634 0
30 −5.873 320.661 100 3.718 −0.853 689 0
31 −7.086 10000 87 5.552 −0.031 706 2
32 −7.577 6796.3 86 5.587 −0.182 728 2
33 −4.412 510.221 100 3.68 −0.551 698 0
34 −5.151 172.409 93 3.016 −1.109 686 0
35 −8.625 4490.1 91 6.747 −0.499 805 0
36 −8.387 6574.5 95 7.030 −0.282 792 2
37 −6.820 268.314 93 5.145 −0.940 718 1
38 −6.864 312.057 100 4.968 −1.039 761 0
39 −6.599 229.964 100 4.662 −1.184 784 0
40 −6.423 320.420 100 4.635 −1.002 737 0
Log S: Predicted aqueous solubility (acceptable range: −6.5-0.5), MDCK cell permeability in nm/second (acceptable range: <25 poor,  >500 great), percentage of 
human oral absorption (<25% is poor and >80% is high), predicted octanol/water partition co-efficient (acceptable range: −2.0-6.5), predicted blood brain barrier 
permeability (acceptable range: −3.0-1.2), total solvent accessible surface area (acceptable range: 300.0-1000.0), Lipinski’s rule of five (maximum 4), ADME: Absorption, 
distribution, metabolism, excretion
range of 81 to 100%. Compounds 2, 7-10, 12, 13, 20, 30, 33, 38, 39, and 
40 showed 100% oral absorption. For selected lead compounds, the 
partition coefficient (QP log Po/w) was within the permissible range of 
−2.0-6.5 except for compounds 16, 35 and 37 (6.560, 6.747, and 7.030, 
respectively). Brain/blood partition coefficient (QP log BB) and SASA 
were also found to be within satisfactory range. Violations of Lipinski’s 
rule of five were also calculated [20]. All compounds followed Lipinski’s 
rule, thereby indicating their potential as a drug-like molecule. Most of 
the compounds do not follow the acceptable range for predicted aqueous 
solubility (Log S) and predicted apparent MDCK cell permeability 
(PMDCK). Table 2 showed some pharmacokinetic properties calculated 
for chroman analogs (1-40) by Qikprop simulation.
CONCLUSION
Various chroman analogs were designed and examined for its 
binding ability by molecular docking studies. From the docking 
studies conducted on the alpha ligand-binding domain of ER (PDB: 
1YIM), it can be concluded that compound 38 (−8.16) showed better 
docking score than standard drug anastrazole (−7.86). Most of the 
pharmacokinetic properties conducted by Qikprop were within 
the permissible range. Therefore, the present work suggests these 
molecules as promising leads for the development of new anti-breast 
cancer agents.
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Fig. 1: Docked conformations of compounds 38 (a), 36 (b), and 
35 (c) important amino acid residues of alpha ligand‑binding 
domain of estrogen receptor. Ligands are shown as ball and stick, 
and interacting amino acids are shown as sticks. H‑bonds are 
displayed in red dotted line
Fig. 2: Interaction diagram for compound 38. Hydrogen bond 
interaction represented by dotted lines. The hydrophobic 
residues located at the opening of the active site were 
represented as green lines
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